Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

NCT05834244 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT05834244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05834244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
October 26, 2023
Completion date
June 30, 2028
Enrollment
32 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia